Evolent Health
About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Employees: 4,700
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]
45% more capital invested
Capital invested by funds: $2.49B [Q2] → $3.61B (+$1.12B) [Q3]
38% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 42
7% more funds holding
Funds holding: 243 [Q2] → 259 (+16) [Q3]
2.14% less ownership
Funds ownership: 112.31% [Q2] → 110.17% (-2.14%) [Q3]
10% less call options, than puts
Call options by funds: $75.4M | Put options by funds: $84.2M
20% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 92
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
31%
upside
Avg. target
$22
93%
upside
High target
$35
207%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
JP Morgan Anne Samuel 41% 1-year accuracy 14 / 34 met price target | 31%upside $15 | Overweight Maintained | 22 Nov 2024 |
Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target | 145%upside $28 | Outperform Maintained | 18 Nov 2024 |
Citigroup Daniel Grosslight 41% 1-year accuracy 7 / 17 met price target | 84%upside $21 | Buy Maintained | 13 Nov 2024 |
RBC Capital Sean Dodge 50% 1-year accuracy 21 / 42 met price target | 75%upside $20 | Outperform Reiterated | 12 Nov 2024 |
Barclays Stephanie Davis 56% 1-year accuracy 9 / 16 met price target | 67%upside $19 | Overweight Maintained | 11 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
2 days ago
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.
Negative
Zacks Investment Research
1 week ago
New Strong Sell Stocks for December 12th
ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024.
Positive
Seeking Alpha
1 month ago
Evolent Health: A Shot At Revival After Market Bruising
Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual revenue growth, driven by rate increases and strategic partnerships. EVH stock appears undervalued with a P/E ratio of 16.57, suggesting a potential contrarian buy opportunity given its long-term growth prospects.
Neutral
Seeking Alpha
1 month ago
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Benzinga
1 month ago
Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Negative
Zacks Investment Research
1 month ago
Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago.
Neutral
PRNewsWire
1 month ago
Evolent Announces Third Quarter 2024 Results
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.
Positive
Zacks Investment Research
1 month ago
Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Positive
Zacks Investment Research
1 month ago
Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again
Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charts implemented using Lightweight Charts™